Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12726581 | 0.92 | TDP1 (0.38) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL12766090 | 0.92 | THRA (0.38) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL1019663 | 0.90 | FLT3 (0.40) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL1022138 | 0.88 | HSP90AA1 (0.42) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL1018764 | 0.88 | HSP90AA1 (0.44) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL1018517 | 0.88 | GLRA1 (0.44) | LMNAEGFRHTTALDH1A1 | |
| SCHEMBL31425472 | 0.86 | P2RX3 (0.41) | FYNTDP1LMNAEGFRALDH1A1 | |
| SCHEMBL1019040 | 0.86 | P2RX3 (0.41) | FYNTDP1LMNAEGFRALDH1A1 | |
| SCHEMBL14930787 | 0.86 | CYP3A4 (0.51) | LMNAEGFRBACE1HTTCYP3A4 | |
| SCHEMBL4999364 | 0.85 | CTSD (0.39) | LMNAEGFRBACE1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568128-B1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIV KANSAS (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3568128-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | The University of Kansas (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190337894-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2019-11-07 | — | — | US | disclosed |
| WO-2018132769-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337894-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | HSP90AB1, HSP90AB2P, HSP90B1 | CHEK1 2002/4885AURKA 1835/4885DAPK3 506/4885 |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | CHEK1 2002/4885AURKA 1835/4885DAPK3 506/4885 |
| US-20130210820-A1 | Pharmaceutical Compounds | SLC10A1, MAPT, SLC5A1 | CHEK1 4568/4885AURKA 1235/4885DAPK3 3906/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | CHEK1 4857/4885AURKA 1415/4885DAPK3 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.